The conversation discusses potential future hair loss treatments, including SCUBE3, hairfollicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.
HairClone is developing cell replacement treatments to rejuvenate and generate hairfollicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
The conversation discusses why DHT (dihydrotestosterone) negatively affects scalp hair but promotes growth elsewhere on the body. Various opinions include genetic predispositions, differences in hairfollicle reactions to DHT, and the potential role of Omega-3 in reducing inflammation and promoting hair health.
TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hairfollicle sensitivity to DHT.
CRISPR Cas9 could potentially treat baldness by targeting specific genes in hairfollicles without affecting other body functions. There is optimism about its future use, despite ethical concerns and the current reliance on treatments like minoxidil and finasteride.
Scientists have grown natural-looking hair from stem cells, potentially revolutionizing hair growth treatments. Concerns include cost, DHT resistance, and the need for future procedures.
The conclusion of this conversation about hair loss is that genetics play a significant role in determining hair loss, and specific treatments like finasteride may not be effective against certain compounds like masteron and trenbolone.
Cannabis and THC may have mixed effects on hair, with some studies suggesting potential negative impacts on hair growth in isolated hairfollicles, but these results are hard to apply to living humans. Treatments like minoxidil and finasteride are commonly used for hair loss, and the effects of cannabis might be neutral or vary based on individual factors.
Hair loss treatments like finasteride, minoxidil, and hair transplants have side effects and limitations. There is hope for future advancements in stem cell therapy and hairfollicle regeneration, though skepticism about their effectiveness and timeline persists.
There is no permanent cure for hair loss; treatments like finasteride, minoxidil, and hair transplants require ongoing use and are not universally effective. Genetic complexity and financial incentives for ongoing treatments hinder the development of a definitive cure.
PP405 is a promising molecule that may reactivate dormant hairfollicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
Hair loss is influenced by genetics and sensitivity to hormones like DHT. Treatments like Minoxidil and finasteride are commonly used, and baldness persists as it doesn't affect reproductive success.
The conversation discusses the lack of significant advancements in hair loss treatments since the introduction of finasteride 22 years ago, with many expressing frustration over the failure of new projects and skepticism about future developments. Some users mention hair transplants and other potential alternatives like Alfatradiol and Fluridil, but acknowledge finasteride's dominance in the market due to its effectiveness and affordability.
New hair loss treatments like PP-405, AMP-303, and SCUBE3 are being discussed, but none are confirmed to fully restore hairlines. Current treatments like Minoxidil, Finasteride, and RU58841 are still widely used, with some hope for future advancements in hair regrowth.
A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hairfollicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.
DHT affects hairfollicles, contributing to hair loss, but the exact mechanism is unclear. Treatments like finasteride and minoxidil are used to manage hair loss, though they may have side effects and varying effectiveness.
PP405 may reactivate dormant hairfollicles but won't replace hair transplants or resurrect dead follicles. Its effectiveness, cost, and impact compared to treatments like minoxidil and finasteride are uncertain.
A permanent hair loss solution could involve reprogramming hairfollicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
Hair loss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.
Creatine generally does not affect hair loss, but some report increased shedding due to higher DHT levels. Many manage hair loss with dutasteride, finasteride, and minoxidil.
JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hairfollicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.
MCL-1 is important for hairfollicle stem cell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
PP405 shows promise for reactivating hairfollicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.
The conversation discusses concerns about the potential risk of cancer from creating new hairfollicles through microneedling, due to stem cell division. Specific treatments mentioned include microneedling, caffeine-containing anti-hair loss shampoos, and other unspecified topicals.
AI advancements, like AlphaFold, are speeding up drug discovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hairfollicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
Hairfollicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.